Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SCYNEXIS INCSCYX · Entity 7194 | Director | June 26, 2026 | June 30, 2026 |
| Vaxart, Inc.AVIR · Entity 6654 | Director | May 18, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SCYNEXIS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,750 |
Reported balance
After 2026-06-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 2,875 · Balance 11,750 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2036-06-25 | Direct | 2,875 |
Reported balance
After 2026-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-26 · Grant · Acquired 2,875 · Balance 2,875 F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
Vaxart, Inc.
Report date May 18, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2027-05-18 | Direct | 75,000 |
Reported balance
After 2017-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-18 · Grant · Acquired 20,000 · Balance 75,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zynerba Pharmaceuticals, Inc.
Report date October 10, 2023 · Filed October 11, 2023
Section 16 reporting ended · disclosed 2023-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-10-10 · Other · Disposed 566,722 · Balance 370,000 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Row 2 · 2023-10-10 · Grant · Acquired 240,000 · Balance 610,000 F3: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest Row 3 · 2023-10-10 · Other · Disposed 610,000 · Balance 0 F4: This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-10-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-10-10 · Other · Disposed 26,595 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). F5: TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-10-10 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2023-10-10 · Other · Disposed 13,297 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). F5: TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2023-10-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-10 · Disposition to issuer · Disposed 190,000 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7) F7: (Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2)
F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment").
F3: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest
F4: This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest.
F5: TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7)
F7: (Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001219866-26-000002 · ownership.xml · derivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,875 Underlying: Common Stock · 2,875 shares Expires 2036-06-25 F3 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 2,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001219866-26-000002 · ownership.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,750 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2 · balance_after: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000950170-25-091555 · ownership.xml · derivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-25 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091555 · ownership.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-24-076203 · ownership.xml · derivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-19 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076203 · ownership.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Disposition to issuerStock Option (Right to Buy) · Derivative | 190,000 | Not disclosed Strike: $2.41 | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · derivative · entry 6 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires 2032-01-26 F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7) F7 · price: (Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7) F7 · derivative.exercise_date: (Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 13,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · nonDerivative · entry 5 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). F5 · ownership.nature: TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 26,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · nonDerivative · entry 4 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). F5 · ownership.nature: TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 610,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · nonDerivative · entry 3 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · shares: This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. F4 · price: This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 240,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,000 F3 · shares: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest F3 · price: This line item represents unvested restricted stock awards ("RSAs") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 13:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 566,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047723 · form4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 20:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 17,830 | $1.33 | $23,637.23 |
DisclosureSEC source: 0001062993-23-018018 · form4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,722 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 64,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-018018 · form4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 954,552 F1 · price: On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:58 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-029034 · ownership.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 23, 2023 20:15 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029630 · ownership.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 22:10 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Tax withholdingCommon Stock | 12,547 | $0.60 | $7,484.29 |
DisclosureSEC source: 0000899243-23-004442 · doc4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,805 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:10 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 45,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-004442 · doc4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,352 F1 · price: The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 01:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Tax withholdingCommon Stock | 11,726 | $0.60 | $6,979.32 |
DisclosureSEC source: 0000899243-23-003732 · doc4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,946 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 42,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-003732 · doc4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,672 F1 · price: The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date. Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 22:25 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001384 · form4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,235 F2 · shares: The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:25 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 35,453 | $0.60 | $21,193.80 |
DisclosureSEC source: 0001062993-23-001384 · form4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,235 F1 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:05 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 11,899 | $1.10 | $13,088.90 |
DisclosureSEC source: 0001062993-22-016555 · form4.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,688 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:05 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 43,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-016555 · form4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,587 F1 · price: On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 43,164 performance-based restricted stock awards granted in a prior year. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001209191-22-038652 · doc4.xml · derivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038652 · doc4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001062993-22-001787 · form4.xml · derivative · entry 4 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-01-26 F3 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:28 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-001787 · form4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,423 F1 · shares: The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 12:27 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001209191-21-041821 · doc4.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 21:21 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 161,867 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001192482-21-000113 · edgar.xml · derivative · entry 4 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,867 Underlying: Common Stock · 161,867 shares Expires 2031-01-21 F3 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 21:21 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 107,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000113 · edgar.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,423 F1 · shares: These restricted stock awards will fully vest on January 21, 2023, subject to continued employment with the Company through the applicable vesting date. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 2,500 | Not disclosed Strike: $8.25 | Not disclosed |
DisclosureSEC source: 0001209191-20-064954 · doc4.xml · derivative · entry 3 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2024-06-21 F1 · price: Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 2,500 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0001209191-20-064954 · doc4.xml · derivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2021-12-21 F1 · price: Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 5,000 | $6.25 | $31,250.00 |
DisclosureSEC source: 0001209191-20-064954 · doc4.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:07 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-041731 · doc4.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| July 06, 2020 Filed Mar 31, 2021 20:00 UTC Amendment | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-023757 · doc4a.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:37 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 162,480 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000095 · edgar.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,480 Underlying: Common Stock · 162,480 shares Expires 2030-01-30 F1 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 17:31 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-19-038194 · doc4.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 21:15 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000049 · edgar.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2019-01-24 F1 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company. Read SEC document |
| January 24, 2019 Filed Jan 30, 2019 21:12 UTC Amendment | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000063 · edgar.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company. F2 · derivative.expiration_date: Due to a clerical error, the reporting person is filing this Amendment to correct the expiration date of the stock options from 1/24/2019 to 1/24/2029. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 14:34 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-19-004901 · doc4.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: One third of the shares subject to this option vest on the one year anniversary of the grant date, and 1/36 of the shares subject to the option vest on each of the next 24 months thereafter. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 20:32 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 15,000 | $5.96 | $89,422.50 |
DisclosureSEC source: 0001192482-18-000386 · edgar.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,512 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.78 to $6.07, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 21:10 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 81,000 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0001192482-18-000040 · edgar.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2028-01-11 F1 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:30 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.49 Strike: $0.49 | $9,800.00 |
DisclosureSEC source: 0001437749-17-009787 · rdgdoc.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Read SEC document |
| May 15, 2017 Filed May 16, 2017 12:50 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 1,500 | $19.57 | $29,355.00 |
DisclosureSEC source: 0001123292-17-000930 · edgar.xml · nonDerivative · entry 2 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,512 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $19.50 to $19.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| May 12, 2017 Filed May 16, 2017 12:50 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 3,500 | $19.76 | $69,160.00 |
DisclosureSEC source: 0001123292-17-000930 · edgar.xml · nonDerivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,012 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $19.72 to $19.85, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 21:21 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001123292-17-000262 · edgar.xml · derivative · entry 1 ANIDO ARMANDO · CIK 0001219866 · Director · Chairman & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.